Supplementary Material for: Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

<b><i>Aim:</i></b> The aim of the study was to assess the acceptance of patients with opioid use disorder (OUD) to switching their opioid dependence treatment (ODT) for a prolonged-release buprenorphine (PRB) injection according to their prior ODT (buprenorphine/naloxone [B/N] or methadone). <b><i>Methods:</i></b> This was an observational, retrospective/cross-sectional, multicentre study of adult patients diagnosed with OUD on ODT. Data collected from diaries were analysed to know their interest and opinion on PRB. Questions with fixed response options were included, and several Likert scales were used. <b><i>Results:</i></b> A total of 98 patients were enrolled (B/N: 50.0%, methadone: 50.0%). The mean age was 46.9 ± 8.43 years and 79.6% were males. PRB was similarly perceived by both groups in most variables analysed, receiving a mean score of 7.2/10 (B/N: 7.4, methadone: 7.0; <i>p</i> = 0.520), and approximately 65% of patients said they were willing to switch to PRB (B/N: 63.3%, methadone: 65.3%; <i>p</i> = 0.833). Of these, a higher percentage in the B/N group considered that switching would be easy/very easy (B/N: 90.3%, methadone: 46.9%; <i>p</i> &lt; 0.001) and that they would start PRB when available (B/N: 64.5%, methadone: 34.3%; <i>p</i> = 0.005). More than 90% would prefer the monthly injection (B/N: 93.6%, methadone: 100%; <i>p</i> = 0.514). One-third of patients in both groups were unsure/would not switch their ODT to PRB (B/N: 36.7%, methadone: 34.7%; <i>p</i> = 0.833). The main reason was administration by injection. <b><i>Conclusion:</i></b> Two-thirds of patients would switch their treatment for PRB, and most patients on B/N considered that switching would be easy. PRB could be a suitable alternative for OUD management.

<b><i>研究目的：</i></b> 本研究旨在评估阿片类使用障碍（opioid use disorder, OUD）患者根据其既往阿片类依赖治疗（opioid dependence treatment, ODT）方案（丁丙诺啡/纳洛酮[buprenorphine/naloxone, B/N]或美沙酮），更换为缓释丁丙诺啡（prolonged-release buprenorphine, PRB）注射剂的接受度。<b><i>研究方法：</i></b> 本研究为一项针对接受ODT治疗且确诊OUD的成年患者的观察性、回顾性/横断面多中心研究。研究分析了从患者日记中收集的数据，以了解其对PRB的兴趣与看法。研究纳入了固定选项作答的问卷，并采用了多个李克特（Likert）量表进行评估。<b><i>研究结果：</i></b> 共计纳入98例患者（B/N组50.0%，美沙酮组50.0%）。患者平均年龄为46.9±8.43岁，其中男性占比79.6%。在多数分析变量中，两组患者对PRB的认知水平相近，总体平均评分为7.2/10（B/N组7.4，美沙酮组7.0；p=0.520）；约65%的患者表示愿意更换为PRB治疗（B/N组63.3%，美沙酮组65.3%；p=0.833）。在愿意更换治疗的患者中，B/N组认为更换过程“容易/非常容易”的占比更高（B/N组90.3%，美沙酮组46.9%；p<0.001），且愿意在PRB可用时立即开始治疗的占比也更高（B/N组64.5%，美沙酮组34.3%；p=0.005）。超过90%的患者更倾向于每月一次的注射剂型（B/N组93.6%，美沙酮组100%；p=0.514）。两组各有三分之一的患者表示不确定或不愿将ODT更换为PRB（B/N组36.7%，美沙酮组34.7%；p=0.833）。患者不愿更换的主要原因为注射给药方式。<b><i>研究结论：</i></b> 三分之二的患者愿意更换为PRB治疗，且多数B/N组患者认为更换过程较为简便。PRB可作为OUD管理的合适替代治疗方案。